Charlie Stewart

Charlie Stewart is an associate in Goodwin’s Antitrust and Competition practice. He assists clients with addressing antitrust and competition issues related to merger reviews, compliance, government investigations, litigation, and other regulatory issues. He has significant experience in premerger counseling, including compliance with Hart-Scott-Rodino premerger requirements, and has also successfully guided clients through several investigations before the Antitrust Division of the United States Department of Justice and the Federal Trade Commission. Charlie has further assisted clients responding to litigation and internal investigations after allegations of anticompetitive conduct.

Charlie has represented clients in many industries, including life sciences, healthcare, technology, defense, aerospace, financial products and technology, and consumer goods.

Charlie is committed to pro bono service and represented clients in collaboration with the New England Innocence Project, California Innocence Project, Project Citizenship, and the Washington Legal Clinic for the Homeless.

Charlie’s recent representative experience includes:

• Proteologix in its acquisition by Johnson & Johnson for $850 million with potential for additional milestone payment
• AVROBIO, Inc. in its merger with Tectonic Therapeutic in all-stock transaction
• Shanghai Argo Biopharmaceutical Co., Ltd. on its multi-program RNAi license and strategic collaborations with Novartis
• Q32 Bio Inc. in its merger with Homology Medicines, Inc. in an all-stock transaction
• Graphite Bio in its merger with LENZ Therapeutics in an all-stock transaction
• KBP Biosciences in its sale of ocedurenone to Novo Nordisk for up to $1.3 billion
• EQRx in its acquisition by Revolution Medicines in an all-stock transaction
• Korro Bio in its merger with Frequency Therapeutics in an all-stock transaction with concurrent $117 million financing
• Versanis Bio in its acquisition by Eli Lilly and Company in a transaction valued up to $1.925 billion
• SunMed in its acquisition of Vyaire Medical’s Respiratory and Anesthesia Consumables business
• SunMed Group Holdings, LLC in its acquisition of Avanos Medical, Inc.’s Respiratory Health business
• GreenLight Biosciences Holdings, PBC in its acquisition by a consortium led by Fall Line Capital, LLC
• Forma Therapeutics in its acquisition by Novo Nordisk for $1.1 billion
• Nimbus Therapeutics in its sale of Allosteric Tyk2 Inhibitor Program to Takeda for $4 billion upfront and up to $6 billion total following antitrust litigation against Celgene and Bristol Myers Squibb to enjoin their attempted acquisition of the same program 
• Sichuan Kelun-Biotech Biopharmaceutical in its exclusive license and ADC collaboration agreement with Merck for $9.5 billion
• Owens Corning in its acquisition of WearDeck from JR Plastics Corporation*
• Parker Hannifin in its acquisition of Meggitt PLC for £6.3 billion*
• Monster Beverage in its acquisition of CANarchy Craft Brewery Collective LLC for $330 million*
• City of Hope in its acquisition of Cancer Treatment Centers of America*
• Procter & Gamble in its acquisition of TULA Life*
• The Duchossois Group in its sale of The Chamberlain Group LLC to Blackstone*
• Follett in its sale of Follett School Solutions to Francisco Partners*
• Cooper Tire & Rubber Company in its sale to The Goodyear Tire & Rubber Company for $2.5 billion*

*Denotes experience prior to joining Goodwin.

Charlie is a contributor to Goodwin’s Antitrust Trends in Technology, Life Sciences, and Healthcare series, which provides quarterly analysis and commentary on antitrust developments. His other publications include:

• Co-Author, “United States: FTC Pharma Scrutiny Expected to Continue Following Step Up in Killer Acquisition Enforcement,” Global Competition Review’s The Guide to Life Sciences, August 14, 2024
• Co-Author, “District Court Grants Welsh Carson’s Motion to Dismiss in FTC’s “Roll-Up” Monopolization Case; Case Against U.S. Anesthesia Partners Continues,” Goodwin Client Alert, May 15, 2024
• Co-Author, “United States: Scepticism of Tech Transactions Sparks a Step-Up in Merger Enforcement,” The Global Competition Review, March 11, 2024
• Co-Author, “Antitrust & Competition Life Sciences Year in Review 2023,” Goodwin Client Alert, February 22, 2024
• Co-Author, “US Antitrust Agencies Release Revised Draft Merger Guidelines,” Goodwin Client Alert, December 19, 2023
• Co-Author, “Sanofi Drops Maze Licensing Deal After FTC Challenge,” Goodwin Client Alert, December 12, 2023
• Co-Author, “United States: Trends of Agency Scrutiny on Pharmaceutical Transactions Expected to Shift Amid Rise in Deal Activity,” The Global Competition Review, November 2, 2023